<SEC-DOCUMENT>0000059478-21-000213.txt : 20211026
<SEC-HEADER>0000059478-21-000213.hdr.sgml : 20211026
<ACCEPTANCE-DATETIME>20211026070635
ACCESSION NUMBER:		0000059478-21-000213
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20211026
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211026
DATE AS OF CHANGE:		20211026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		211345910

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20211026.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:8b4c3870-ed11-4d50-86ca-c3b6190d30cd,g:830a719d-b847-408f-9e26-fd7970cff3e0,d:26864a37677a43f0aa51bbf677f8b8ad--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:lly="http://www.lilly.com/20211026" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20211026</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF80L2ZyYWc6MzdkMDcyNzA4NDFhNDcyMWI1ZDExYmNjYWQyZGIyMmMvdGFibGU6MjVkNDM5MDg5MTNmNDdmNjhjNmJiY2FiYmRhNmQzMzgvdGFibGVyYW5nZToyNWQ0MzkwODkxM2Y0N2Y2OGM2YmJjYWJiZGE2ZDMzOF8yLTEtMS0xLTE_c6cffe31-ec6e-4d11-8ca4-a3a8bbbb807a">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF80L2ZyYWc6MzdkMDcyNzA4NDFhNDcyMWI1ZDExYmNjYWQyZGIyMmMvdGFibGU6MjVkNDM5MDg5MTNmNDdmNjhjNmJiY2FiYmRhNmQzMzgvdGFibGVyYW5nZToyNWQ0MzkwODkxM2Y0N2Y2OGM2YmJjYWJiZGE2ZDMzOF81LTEtMS0xLTE_fa4d1695-b983-401c-b307-362ba14bb789">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20211026.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie995d89d5c494c239211a78a6682af37_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f68d019fc444398a863e31316ec594_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014ec31d847549518d3d26c2b459250e_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-26</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i26864a37677a43f0aa51bbf677f8b8ad_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg1_130b7be1-99ae-4aeb-b966-80a8ffe6bbae">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xNTk_c8c3b0ff-1444-40d0-81d7-6d3f567140cc">October 26, 2021</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg2_685a63f9-e991-4e60-b865-0ae69d516235">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ODNiMDNlNDA1ZWIwNDIxMTgxMDcwMWU0MDQ0NTI3NTIvdGFibGVyYW5nZTo4M2IwM2U0MDVlYjA0MjExODEwNzAxZTQwNDQ1Mjc1Ml8wLTAtMS0xLTE_f3fdcec2-69db-4d68-bb70-e99cb5445ec9">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ODNiMDNlNDA1ZWIwNDIxMTgxMDcwMWU0MDQ0NTI3NTIvdGFibGVyYW5nZTo4M2IwM2U0MDVlYjA0MjExODEwNzAxZTQwNDQ1Mjc1Ml8wLTItMS0xLTE_f6a04847-8152-4138-911e-7346d721f933">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ODNiMDNlNDA1ZWIwNDIxMTgxMDcwMWU0MDQ0NTI3NTIvdGFibGVyYW5nZTo4M2IwM2U0MDVlYjA0MjExODEwNzAxZTQwNDQ1Mjc1Ml8wLTQtMS0xLTE_6a4ed9b5-9532-4aee-b942-c85c7f4a9d78">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:21.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8wLTAtMS0xLTE_ca3d0b97-9a43-4d90-b025-7ece79c76d4d">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8xLTAtMS0xLTE_3ec89721-3629-4810-94f8-12039d10c548">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8xLTEtMS0xLTE_02d0b1cc-0c02-47c9-95ce-e756b29b9a55">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8xLTItMS0xLTE_5e6ad306-5216-4fec-8fb8-61b2621ce0ea">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg3_4e80422e-d2a6-4a89-b6aa-c12ecfd1ea78">317</ix:nonNumeric>) <ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg4_3924a600-1729-4f22-b80e-731c9ac78fc8">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjY4MGQ3NjBmZDZjNGNkMjkyZWE1NWE4Y2YzMzM1OWEvdGFibGVyYW5nZTpiNjgwZDc2MGZkNmM0Y2QyOTJlYTU1YThjZjMzMzU5YV8wLTAtMS0xLTE_181f1f20-29e3-4b85-b771-ec8692b92fce">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6MTU5YTk4ZmNhYjc3NDYxYzhmZWIyYmZkMzM1MmFmN2UvdGFibGVyYW5nZToxNTlhOThmY2FiNzc0NjFjOGZlYjJiZmQzMzUyYWY3ZV8wLTAtMS0xLTE_1e03e2b1-4a24-4929-9a6f-fa6cc690c42d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ZWZmODhjODViNmFmNDY3Yzg0MWU4NTc1MTEyYjBhMDEvdGFibGVyYW5nZTplZmY4OGM4NWI2YWY0NjdjODQxZTg1NzUxMTJiMGEwMV8wLTAtMS0xLTE_29aba61b-b8a4-4a39-aa02-fd35f4bdd490">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6OTRhMTkxYzkxNDZhNDFmYWJiMDEzNGE1ZjkzZTI3ZjYvdGFibGVyYW5nZTo5NGExOTFjOTE0NmE0MWZhYmIwMTM0YTVmOTNlMjdmNl8wLTAtMS0xLTE_3a4086dd-1d7e-4503-b4e4-c7405f8ea401">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xLTAtMS0xLTE_03b4b0f4-671d-41e0-a658-65cff62f9552">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xLTItMS0xLTE_6af81dc6-ddaf-4f12-9658-af0c3d94e2b1">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xLTQtMS0xLTE_8c3ecff4-69fb-49b5-b8b8-625bffe35d5e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8yLTAtMS0xLTE_9d77ba04-d9db-4f33-9a4f-6d2bf77afacc">1.000% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8yLTItMS0xLTE_fb1bcc66-d82c-443f-856f-5550532513fd">LLY22</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8yLTQtMS0xLTE_decca609-e594-4e4f-bebb-2bf6336934d9">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8zLTAtMS0xLTE_3659520d-e859-44d7-8aba-d4841ac628e5">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8zLTItMS0xLTE_78a0dded-9d92-431c-add4-bd72d4089b12">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8zLTQtMS0xLTE_2a4b07d2-b437-463b-bca4-4d3d9a263989">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF80LTAtMS0xLTE_463c8308-be9b-41a6-971f-89c74eaf1693">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF80LTItMS0xLTE_04d16166-c797-4620-9651-906ada3e56e6">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF80LTQtMS0xLTE_c3dc6166-d480-4690-87ec-8d85ee672df8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF81LTAtMS0xLTE_19cac08e-4f03-45fd-b38c-b58807fab668">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF81LTItMS0xLTE_7d6ae5de-4230-4eba-a98b-580fe930eee8">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF81LTQtMS0xLTE_66c31916-e09d-4924-967b-4be00e8f06a7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF82LTAtMS0xLTE_7a0be2ad-3bd4-48a4-b0af-5fca7c67440b">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF82LTItMS0xLTE_1eebdf03-04b5-4102-8b87-0bc3c6d6c1cc">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF82LTQtMS0xLTE_99980288-2c50-47d9-bd4c-c148a8a82fa2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTAtMS0xLTIxNjAw_a096810f-302a-49a3-a80e-cc3fa0b97093">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTItMS0xLTIxNzAx_b44bb3c5-ca56-4f0a-9d92-2a2181ceccbc">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTQtMS0xLTIxNzEz_7eb746e7-10e9-463f-9741-79868209cfe9">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTAtMS0xLTE_6ad202ad-f876-42f8-930c-be579d77c497">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTItMS0xLTE_03004c35-d1c3-4411-b640-26f48f71a251">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTQtMS0xLTE_8e1f5b9f-983b-4eac-af03-52b5bbf1eadb">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie995d89d5c494c239211a78a6682af37_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF85LTAtMS0xLTIxNjky_6bb6ad9d-a892-41bc-9824-2e178791b7ee">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie995d89d5c494c239211a78a6682af37_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF85LTItMS0xLTIxNzA0_99a420c5-0d9a-4f29-b6d2-4efe593b6809">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie995d89d5c494c239211a78a6682af37_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF85LTQtMS0xLTIxNzE2_0a27ec01-a25f-44bf-a24c-8ed1a62449a2">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37f68d019fc444398a863e31316ec594_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF84LTAtMS0xLTE_24814ba7-9ecd-4fb7-be5a-b78032e12795">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37f68d019fc444398a863e31316ec594_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF84LTItMS0xLTE_0e5bab82-00a3-40e4-aadc-82d9eb7d8bf5">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i37f68d019fc444398a863e31316ec594_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF84LTQtMS0xLTE_ff8ec5bc-3a5d-4f4c-b476-d7956b243bec">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i014ec31d847549518d3d26c2b459250e_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMS0wLTEtMS0yMTY5NQ_1d79bc23-7d83-452a-b8d4-c1255630ff9a">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i014ec31d847549518d3d26c2b459250e_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMS0yLTEtMS0yMTcwNw_dead5753-7fbf-47a3-84cd-b8609c512a64">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i014ec31d847549518d3d26c2b459250e_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMS00LTEtMS0yMTcxOQ_93d25bf2-9d95-4975-966b-3102badb30a3">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMi0wLTEtMS0yMTY5OA_097e786e-2672-43cb-a79f-6d84bb8cbfac">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMi0yLTEtMS0yMTcxMA_2a12f219-ae93-4d67-bd4a-4dd3fc32e547">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMi00LTEtMS0yMTcyMg_892ecab1-6a4b-46c5-a3ae-9b566f999e0e">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg5_f9b36ded-c8c7-4169-b4b6-cdec85ddaf6d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i26864a37677a43f0aa51bbf677f8b8ad_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated October 26, 2021, announcing the financial results of Eli Lilly and Company for the quarter ended September 30, 2021, including, among other things, unaudited financial results for that period.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q321lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q321lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q321lillysalesandearningsp.htm">October </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q321lillysalesandearningsp.htm">26</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q321lillysalesandearningsp.htm">, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.666%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 26, 2021</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q321lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i23d5469e701244a891cca7da0be968f5_1"></div><div style="min-height:180pt;width:100%"><div style="text-align:right"><img alt="logoa31a.jpg" src="logoa31a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">October 26, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lilly Corporate Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indianapolis, Indiana  46285</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.A. </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1.317.276.2000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:8pt;font-weight:700;line-height:100%">www.lilly.com</font></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58;</font><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Final </font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refer to&#58;</font><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Molly McCully&#59; mccully_molly&#64;lilly.com&#59; (317) 478-5423 (Media)</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jordan Bishop&#59; bishop_jordan&#64;lilly.com&#59; (317) 473-5712 (Media)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Kevin Hern&#59; hern_kevin_r&#64;lilly.com&#59; (317) 277-1838 (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Lilly Reports Robust Third-Quarter 2021 Financial Results </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">as Pipeline Success Strengthens Future Growth Potential </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Revenue in the third quarter of 2021 increased 18 percent, driven by volume growth of 17 percent. When excluding revenue from COVID-19 therapies, revenue growth was 11 percent in both third-quarter and year-to-date 2021. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Key growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo and Cyramza, contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue in the third quarter of 2021, excluding revenue from COVID-19 therapies. </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Revenue from</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> Trulicity, Taltz, Verzenio and Emgality each grew by more than 30 percent versus prior year. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Third-quarter 2021 earnings per share (EPS) decreased to $1.22 on a reported basis and increased to $1.94 on a non-GAAP basis, representing 38 percent growth versus prior year. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Lilly announces today its U.S. submission of tirzepatide in type 2 diabetes using a priority review voucher and initiation of a rolling submission for donanemab to the FDA for accelerated approval in early Alzheimer's disease.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Other notable recent pipeline events include U.S. approvals for new indications for both Verzenio and Jardiance, submission of Jardiance in the U.S. and Europe for heart failure with preserved ejection fraction (HFpEF)</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">and positive Phase 3 readouts for lebrikizumab in atopic dermatitis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:140%">Eli Lilly and Company (NYSE&#58; LLY) announced financial results for the third quarter of 2021 today.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#34;Lilly demonstrated strong performance again this quarter. Revenue attributable to our newer medicines grew more than 35 percent and represented nearly 60 percent of our core business, an important indicator of our long-term growth potential,&#8221; said David A. Ricks, Lilly's chairman and CEO. &#8220;With numerous positive pipeline events this quarter, we have the potential to continue to expand the number of patients we serve through new indications for both Verzenio and Jardiance. We also progressed innovative, potential best-in-class treatment options in areas with high unmet need </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:180pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">through a regulatory submission for tirzepatide in diabetes, the initiation of a rolling submission for donanemab in early Alzheimer&#8217;s disease, the submission of Jardiance in HFpEF, and positive Phase 3 results for lebrikizumab in patients with atopic dermatitis.&#8221;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.899%"><tr><td style="width:1.0%"></td><td style="width:46.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.923%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Quarter</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2020</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">6,772.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">5,740.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">18%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Reported</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,110.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,208.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(8)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Reported<br></font><font style="font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%"><br></font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">(8)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,763.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,289.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">37%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.41&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">38%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Beginning in 2021, non-GAAP measures exclude gains and losses on investments in equity securities and 2020 amounts have been reclassified for comparability. The company&#8217;s 2021 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company&#8217;s business.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i23d5469e701244a891cca7da0be968f5_4"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:140%;text-decoration:underline">Key Events Over the Last Three Months</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Regulatory</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency for tirzepatide for the treatment of adults with type 2 diabetes. A Priority Review Voucher was applied to the NDA, leading to an anticipated review time of eight months from the date of submission according to current FDA priority review timelines. Several additional submissions are planned around the world before the end of 2021.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Th</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">e company initiated rolling submission for donanemab to the FDA for accelerated approval in early Alzheimer&#8217;s disease.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">In October 2021, the company and Pfizer discontinued the global clinical development program for tanezumab, an investigational nerve growth factor inhibitor. This decision was made following receipt of a Complete Response Letter from the FDA for the tanezumab application in osteoarthritis (OA) and a negative opinion adopted by the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use on the </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">tanezumab Marketing Authorization Application in OA. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced that the FDA approved Verzenio</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> as the first and only CDK4&#47;6 inhibitor for certain people with HR+ HER2- high risk early breast cancer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced that the FDA approved a new indication for Erbitux</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in combination with Braftovi</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> for the treatment of certain adult patients with metastatic colorectal cancer with a BRAF V600E mutation.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA expanded the Emergency Use Authorization for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA granted Breakthrough Therapy designation for Jardiance</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> as an investigational treatment for adults with HFpEF, the company and Boehringer Ingelheim announced. The companies submitted Jardiance for regulatory approval in this indication </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to the FDA and</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in Europe.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Jardiance was approved by the FDA to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), the company and Boehringer Ingelheim announced.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA approved an expanded label for the company's rapid-acting insulin, Lyumjev</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous insulin infusion with an insulin pump</font><font style="background-color:#ffffff;color:#212121;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Clinical</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced plans to conduct TRAILBLAZER-ALZ 4, a Phase 3 head-to-head clinical trial comparing donanemab to aducanumab to assess superiority of brain amyloid plaque clearance in early symptomatic Alzheimer's disease. Enrollment is expected to begin this year.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced that in two Phase 3 trials lebrikizumab led to significant improvements at 16 weeks with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis, and key secondary endpoints were achieved, including early onset in skin clearance and itch relief, improvement in interference of itch on sleep and quality of life. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Business Development&#47;Other Developments</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The Office of the Assistant Secretary for Preparedness and Response, alongside the FDA, resumed the shipment and distribution of bamlanivimab and etesevimab administered together. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, the company will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 250,000 doses shipped in the third-quarter of 2021 and the remaining to be shipped in fourth-quarter 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of COVID-19. This agreement helps to provide access to these </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">COVID-19 antibodies b</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">y enabling participating countries in the European Union and European Economic Area to purchase the products directly from Lilly, following national approval for emergency use, or marketing authorization at the EU level. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company announced it will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective Jan. 1, 2022, bringing the list price down to 2008 levels.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company issued its first sustainability bond, for 600.0 million euros in aggregate principal amount. The bond proceeds will be allocated toward environmental projects including pollution prevention, energy efficiency and renewable energy&#59; as well as social projects to increase access to essential services and socioeconomic advancement and empowerment.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The company and Lycia Therapeutics, Inc. announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera protein degradation technology.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="i23d5469e701244a891cca7da0be968f5_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Third-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the third quarter of 2021, worldwide revenue was $6.773 billion, an increase of 18 percent compared with the third quarter of 2020, driven by a 17 percent increase in volume and a 1 percent increase due to the favorable impact of foreign exchange rates, with net realized prices remaining essentially flat. Key growth products, consisting of Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Verzenio, Jardiance, Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue for the third quarter of 2021, excluding COVID-19 therapies. The company recognized worldwide revenue of $423.5 million for COVID-19 therapies during the quarter.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. increased 26 percent, to $3.990 billion, driven by a 22 percent increase in volume and a 4 percent increase due to higher realized prices. The company recognized U.S. revenue of $392.9 million in the third quarter of 2021 for COVID-19 therapies. Excluding that revenue, revenue in the U.S. increased by 14 percent. The increase in U.S. volume was driven by certain key growth products, including Trulicity, Olumiant, Taltz, Jardiance, Verzenio, Retevmo and Emgality. Higher realized prices in the U.S. during the third quarter of 2021 were driven by lower utilization in the 340B segment, unfavorable changes to estimates for rebates and discounts for Trulicity in the third quarter of 2020, and modest list price increases, partially offset by increased rebates to maintain access for products across the business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. increased 8 percent, to $2.783 billion, driven by an 11 percent increase in volume and a 1 percent increase due to the favorable impact of foreign exchange rates, partially offset by a 4 percent decrease due to lower realized prices. The increase in volume outside the U.S. was primarily driven by increased volume for all key growth products. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin increased 21 percent, to $5.342 billion, in the third quarter of 2021 compared with the third quarter of 2020. Gross margin as a percent of revenue was 78.9 percent, an increase of 2.0 percentage points compared to the third quarter of 2020. </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The increase in gross margin percent was p</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">rimarily due to favorable product mix and favorable effect of foreign exchange rates on international inventories sold. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Total operating expenses in the third quarter of 2021, defined as the sum of research and development and marketing, selling, and administrative expenses, increased 8 percent to $3.287 billion compared with the third quarter of 2020. Research and development expenses increased 17 percent to $1.709 billion, or 25.2 percent of revenue, driven primarily by higher development expenses for late-stage assets. Research and development expenses for COVID-19 therapies were approximately $50 million in the third quarter of 2021. Marketing, selling and administrative expenses increased 1 percent to $1.578 billion. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the third quarter of 2021, the company </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">recognized acquired</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in-process research and development charges of $174.0 million related to business development transactions with Protomer Technologies Inc., Kumquat Biosciences Inc., Lycia Therapeutics, Inc., and ProQR Therapeutics N.V. There were no acquired in-process research and development charges recognized in the third quarter of 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">There were no asset impairment, restructuring and other special charges recognized in the third quarter of 2021. In the third quarter of 2020, the company recognized asset impairment, restructuring and other special charges of $101.4 million. These charges were primarily related to severance costs incurred related to restructuring. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income in the third quarter of 2021 was $1.881 billion, compared to</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> $1.278 billion i</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">n the third quarter of 2020. The increase in operating income was driven by higher revenue and, to a lesser extent, lower asset impairment, restructuring and other special charges, partially offset by higher research and development expenses and acquired in-process research and development charges. Operating margin, defined as operating income as a percent of revenue, was 27.8 percent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) was expense of $635.9 million in the third quarter of 2021, compared with income of $158.9 million in the third quarter of 2020. The reduction in other income (expense) was primarily driven by a charge of $405.2 million related to the repurchase of higher-cost debt and unfavorable mark-to-market adjustments on investments in equity securities in the third quarter of 2021 compared to favorable mark-to-market adjustments on investments in equity securities in the third quarter of 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 10.9 percent in the third quarter of 2021, compared with 15.9 percent in the third quarter of 2020. The lower effective tax rate in the third quarter of 2021 compared to the same period in 2020 was primarily due to the income tax impact of the charge related to repurchase of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">higher-cost debt and the unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the same period in 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In the third quarter of 2021, net income and EPS were $1.110&#160;billion and $1.22, respectively, compared with net income of $1.208&#160;billion and EPS of $1.33 in the third quarter of 2020. Net income and EPS in the third quarter of 2021 decreased compared to the same period in 2020 as higher operating income and lower income tax expense were more than offset by a reduction in other income (expense) in 2021. </font></div><div><font><br></font></div><div id="i23d5469e701244a891cca7da0be968f5_10"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Third-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, third-quarter 2021 gross margin increased 18 percent, to $5.351 billion compared with the third quarter of 2020. Gross margin as a percent of revenue was 79.0 percent, a decrease of 0.1 percentage points, driven by favorable product mix (excluding COVID-19 therapies) and favorable effect of foreign exchange rates on international inventories sold, more than offset by lower gross margin on COVID-19 therapies. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income on a non-GAAP basis increased $558.0 million, or 37 percent, to $2.064 billion in the third quarter of 2021 compared with the third quarter of 2020, due to higher gross margin, partially offset by higher research and development expenses. Operating margin was 30.5 percent on a non-GAAP basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) was expense of $7.3 million in the third quarter of 2021, compared with income of $9.9 million in the third quarter of 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 14.3 percent in the third quarter of 2021, compared with 15.0 percent in the third quarter of 2020. The lower effective tax rate in the third quarter of 2021 was driven by a mix of earnings in lower tax jurisdictions partially offset by a decrease in net discrete tax benefits compared to the same period in 2020. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, in the third quarter of 2021 net income increased 37 percent, to $1.764 billion, while EPS increased 38 percent, to $1.94, compared with $1.289 billion and $1.41, respectively, in the third quarter of 2020. The increases in net income and EPS were driven by higher operating income.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information&#34; table later in this press release.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Quarter</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2020</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">(8)%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Charge related to repurchase of higher-cost debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses (gains) on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Acquired in-process research and development</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Partial reversal of COVID-19 antibodies inventory charge</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.94</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.41</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">38%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div id="i23d5469e701244a891cca7da0be968f5_13"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Year-to-Date Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the first nine months of 2021, worldwide revenue increased 19 percent to $20.319 billion, compared with $17.100 billion in the same period in 2020. The increase in revenue was driven by a 19 percent increase in volume and a 2 percent increase due to the favorable impact of foreign exchange rates, partially offset by a 2 percent decrease due to lower realized prices. Excluding $1.425 billion of revenue from COVID-19 therapies, worldwide revenue grew by 11 percent. For the first nine months of 2021, operating income was $4.440 billion, an increase of 9 percent compared with $4.066 billion in the same period of 2020. Reported net income and EPS for the first nine months of 2021 were $3.856 billion and $4.23, respectively, compared with $4.077 billion and $4.47, respectively, for the same </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">period of 2020. The decreases in net income and EPS in the first nine months of 2021 were driven by lower other income (expense), partially offset by higher operating income and lower income taxes. </font></div><div id="i23d5469e701244a891cca7da0be968f5_19"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Year-to-Date Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">For the first nine months of 2021, operating income was $5.921 billion on a non-GAAP basis, an increase </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">of 23 percent compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">$4.809 billion</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%"> in the same period of 2020. Net incom</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">e and EPS, on a non-GAAP basis, were $5.169 billion and $5.67, respectively, compared with $4.083 billion and $4.48, respectively, for the same period of 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information&#34; table later in this press release. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.968%"><tr><td style="width:1.0%"></td><td style="width:61.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Year-to-Date</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2020</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">4.23</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">4.47</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">(5)%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Acquired in-process research and development</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Charge related to repurchase of higher-cost debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies inventory charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net gains on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.22)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.71)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">5.67</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">4.48</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">27%</font></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding.  <br></font></td></tr></table></div><div id="i23d5469e701244a891cca7da0be968f5_25"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Selected Revenue Highlights</font></div><div style="margin-top:1pt;padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Third Quarter</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Year-to-Date</font></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,600.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,106.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">45%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4,588.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">3,565.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">29%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">626.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">656.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(5)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,851.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,907.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(3)%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">457.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">578.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(21)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,626.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,677.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(3)%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">593.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">454.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,565.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,293.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">217.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,176.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">390.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">310.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,058.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">840.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">335.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">234.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">43%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">945.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">631.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">50%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">286.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">305.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(6)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">923.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">935.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(1)%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">406.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">162.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">809.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">446.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">81%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">253.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">252.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">762.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">748.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">192.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">248.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(22)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">650.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">842.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(23)%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">200.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">266.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(25)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">617.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">791.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(22)%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">140.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">91.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">53%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">415.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">252.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">64%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">125.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">84.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">49%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">340.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">205.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">65%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">33.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">11.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">76.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,772.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5,740.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">18%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20,318.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">17,099.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro                                                        </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUA)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR   </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Olumiant includes sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">baricitinib that were made pursuant to EUA                 </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM &#8211; not meaningful                                                                               </font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Third-quarter 2021 worldwide Trulicity revenue was $1.600 billion, an increase of 45 percent compared with the third quarter of 2020. U.S. revenue increased 52 percent, to $1.201 billion, driven by increased demand and, to a lesser extent, higher realized prices due to segment mix, including lower utilization in the 340B program, unfavorable changes to estimates for rebates and discounts in the same period of 2020, and modest list price increases, which were partially offset by increased rebates to maintain access. Revenue outside the U.S. was $398.8 million, an increase of 26 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Humalog revenue decreased 5 percent compared with the third quarter of 2020, to $626.7 million. Revenue in the U.S. decreased 11 percent, to $347.3 million, driven by lower realized prices. Revenue outside the U.S. increased 5 percent, to $279.4 million, driven by the favorable impact of foreign exchange rates and increased volume, partially offset by lower realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Alimta</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Alimta revenue decreased 21 percent compared with the third quarter of 2020, to $457.0 million. U.S. revenue increased 2 percent, to $297.2&#160;million, primarily driven by higher realized prices, partially offset by decreased demand and customer buying patterns. Revenue outside the U.S. decreased 44 percent to $159.8 million, primarily driven by decreased volume due to entry of generic competition and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects continued volume decline for Alimta as a result of the entry of generic competition due to the loss of patent exclusivity in Japan and major European markets. The company expects generic entrants in the U.S. beginning in the first quarter of 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Taltz revenue increased 30 percent compared with the third quarter of 2020, to $593.1&#160;million. U.S. revenue increased 29 percent, to $422.2&#160;million, primarily driven by increased demand, partially offset by lower realized prices. The lower realized prices were driven by increased rebates to gain commercial access and unfavorable segment mix, partially offset by changes to estimates for rebates and discounts. Revenue outside the U.S. increased 33 percent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $170.9 million, primarily driven by increased volume, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company&#8217;s worldwide Jardiance revenue during the third quarter of 2021 was $390.4 million, an increase of 26 percent compared with the third quarter of 2020. U.S. revenue increased 35 percent, to $221.2 million, primarily driven by increased demand. Revenue outside the U.S. was $169.2 million, an increase of 15 percent, driven by increased volume partially offset by the unfavorable impact of foreign exchange rates. Jardiance is part of the company&#8217;s alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Verzenio revenue increased 43 percent compared with the third quarter of 2020, to $335.5 million. U.S. revenue was $199.6 million, an increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of 26 percent, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. was $135.9 million, an increase of 80 percent, primarily driven by increased volume.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humulin</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Humulin revenue decreased 6 percent compared with the third quarter of 2020, to $286.7 million. U.S. revenue decreased 10 percent, to $193.4 million, driven by lower realized prices and, to a lesser extent, decreased demand. Revenue outside the U.S. increased </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2 percent, to $93.4 million, due to higher realized prices and, to a lesser extent, the favorable impact of foreign exchange rates, largely offset by decreased volume. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Olumiant revenue was $406.9 million, an increase of $244.9 million compared with the third quarter of 2020. U.S. revenue was $194.0 million, representing growth of $179.5 million compared with the third quarter of 2020, driven by utilization for the treatment of hospitalized patients with COVID-19 </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">during the third quarter of 2021.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> Revenue outside the U.S. was $212.9 million, an increase of 44 percent, driven by increased volume, partially offset by lower realized prices. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Cyramza</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Cyramza revenue remained essentially flat compared with the third quarter of 2020, at $253.4&#160;million. U.S. revenue was $84.8&#160;million, a decrease of 10 percent, primarily driven by decreased demand</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">partially offset by higher realized prices. Revenue outside the U.S. was $168.6&#160;million, an increase of 7 percent, driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Basaglar</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Basaglar revenue was $192.8 million, a decrease of 22 percent compared with the third quarter of 2020. U.S. revenue decreased</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">36 percent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">,</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> to $114.7 million, driven by continued competitive pressures that resulted in lower realized prices and, to a lesser extent, decreased demand. Due to competitive pressures, continued price decline and loss of market share over time is expected. Revenue outside the U.S. increased 12 percent, to $78.1&#160;million, driven by increased volume. Basaglar is part of the company&#8217;s alliance with Boehringer Ingelheim. Lilly reports as cost of sales payments made to Boehringer Ingelheim for royalties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Forteo</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, worldwide Forteo revenue decreased 25 percent compared with the third quarter of 2020, to $200.9 million. U.S. revenue decreased 24 percent, to $109.6 million, driven by decreased demand and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 25 percent to $91.3&#160;million, primarily driven by decreased volume. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects further volume declines for Forteo as a result of the entry of generic and biosimilar competition due to the loss of patent exclusivity in the U.S., Japan and major European markets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, Emgality generated worldwide revenue of $140.0 million, an increase of 53 percent compared with the third quarter of 2020. U.S. revenue was $99.9 million, an increase of 23 percent, driven by increased demand and higher realized prices. Revenue outside the U.S. was $40.1 million, an increase of $30.0 million compared with the third quarter of 2020, driven by increased demand.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Tyvyt</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, the company's Tyvyt revenue in China was $125.6 million, an increase of 49 percent compared with the third quarter of 2020, driven primarily by increased demand. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Tyvyt is part of the company&#8217;s alliance with Innovent. Lilly reports total sales of Tyvyt made by Lilly as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. Lilly also reports as revenue a portion of the gross margin for Tyvyt sales made by Innovent.&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Retevmo</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For the third quarter of 2021, Retevmo generated U.S. revenue of $29.2 million compared to revenue of $22.5 million in the second quarter of 2021. Retevmo launched outside the U.S. during the second quarter of 2021 and generated revenue of $4.4&#160;million in the third quarter of 2021. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i23d5469e701244a891cca7da0be968f5_34"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2021 Financial Guidance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:174%">The company has updated certain elements of its 2021 financial guidance on both a reported and non-GAAP basis. Earnings per share for 2021 are now expected to be in the range of $6.38 to $6.48 on a reported basis and $7.95 to $8.05 on a non-GAAP basis. The update to the company's 2021 financial guidance reflects adjustments shown in the reconciliation table below.  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.547%"><tr><td style="width:1.0%"></td><td style="width:55.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.995%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2021<br>Expectations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">% Change vs 2020</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$6.38 to $6.48</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">(6)% to (5)%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.47</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.45</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Charge related to repurchase of higher-cost debt</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.35</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies inventory charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.33</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Net gains on investments in equity securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.22)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$7.95 to $8.05</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">17% to 19%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding                                      </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">(a) includes costs related to business development transactions with Rigel Pharmaceuticals, Inc., Precision Biosciences, Inc., Protomer Technologies Inc., Kumquat Biosciences Inc., Merus N.V., Lycia Therapeutics Inc., ProQR Therapeutics N.V., MiNA Therapeutics Limited, and Asahi Kasei Pharma Corporation. </font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company now anticipates 2021 revenue to be between $27.2 billion and $27.6 billion. This increase reflects additional revenue from COVID-19 antibodies and the underlying core business. Estimated revenue from COVID-19 antibodies is now expected to be approximately $1.3 billion. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) for 2021 is now expected to be expense in the range of $250 million to $150 million on a reported basis and is still expected to be expense in the range of $100 million to $0 on a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;17</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">non-GAAP basis. The company's updated reported guidance reflects the impact of the charge associated with the repurchase of higher-cost debt and unfavorable mark-to-market adjustments on investments in equity securities in the third quarter of 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The 2021 effective tax rate is now expected to be approximately 11 percent on a reported basis, reflecting primarily the tax impacts of the charges related to repurchase of higher-cost debt and acquired IPR&#38;D, as well as unfavorable mark-to-market adjustments on investments in equity securities in the third quarter of 2021. The 2021 effective tax rate is still expected to be approximately 13 percent on a non-GAAP basis. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;18</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company&#8217;s 2021 financial guidance&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2021 Guidance</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Updated</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$26.8 to $27.4 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$27.2 to $27.6 billion</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 75%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 79%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Marketing, Selling &#38; Administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.2 to $6.4 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.9 to $7.1 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$375 to $475 million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(250) to $(150) million</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(100) million to $0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 12%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 11%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 13%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.73 to $6.93</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.38 to $6.48</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.80 to $8.00</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.95 to $8.05</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 24%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 30%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share table above.</font></td></tr></table></div><div id="i23d5469e701244a891cca7da0be968f5_37"></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;19</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the third-quarter 2021 financial results conference call through a link on Lilly&#8217;s website at www.lilly.com. The conference call will begin at 9 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. F-LLY</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management&#8217;s current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;intend&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221;, &#8220;target&#8221;, &#8220;anticipate&#8221; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the impact of the evolving COVID-19 pandemic and the global response thereto&#59; uncertainties related to the company&#8217;s efforts to develop potential treatments for COVID-19&#59; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact of acquisitions and business development transactions and related integration costs&#59; the expiration of intellectual property protection for certain of the company&#8217;s products and competition from generic and&#47;or biosimilar products&#59; the company&#8217;s ability to protect and enforce patents and other intellectual property&#59; changes in patent law or regulations related to data package exclusivity&#59; competitive developments affecting current products and the company&#8217;s pipeline&#59; market uptake of recently launched products&#59; information technology system inadequacies, breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company&#8217;s IT systems, networks, and facilities, or those of third parties with whom the company shares its data&#59; unexpected safety or efficacy concerns associated with the company&#8217;s products&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions related to our facilities&#59; reliance on third-party relationships and outsourcing arrangements&#59; regulatory changes or other developments&#59; regulatory actions regarding currently marketed products&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals&#59; devaluations in foreign currency exchange rates or changes in interest rates, and inflation&#59; changes in tax law, tax rates, or events that differ from the company&#8217;s assumptions related to tax positions&#59; asset impairments and restructuring charges&#59; the impact of global macroeconomic conditions and trade disruptions or disputes&#59; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC)&#59; and regulatory compliance problems or government investigations. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company&#8217;s latest Form 10-K and subsequent Forms 8-K and 10-Q filed with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin glargine injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Braftovi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (encorafenib, Pfizer)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cialis</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tadalafil, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Erbitux</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(R) </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(cetuximab, Lilly) </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (teriparatide of recombinant DNA origin injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (human insulin of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">QBREXZA</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium cloth, Dermira)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company Employment Information</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.842%"><tr><td style="width:1.0%"></td><td style="width:28.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">September 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Employees</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34,914</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">34,960</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;21</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i23d5469e701244a891cca7da0be968f5_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results  (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">18%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,430.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,326.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,262.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3,763.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">40%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,708.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,465.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">17%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,066.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,247.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,577.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,569.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,839.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,567.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">174.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">498.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">294.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">69%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(100)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">161.3&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">31%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,881.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,278.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">47%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,439.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,065.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(83.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(240.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(243.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(559.3)</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">116.1&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">938.1&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(635.9)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(124.3)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">694.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,245.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,437.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(13)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,315.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,760.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">228.8&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(41)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">460.0&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">683.9&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(33)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,110.1&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,208.4&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(8)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3,855.6&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,076.9&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(5)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(8)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</font></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(5)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.74&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">910,751&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">911,423&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="8" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">911,656&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="5" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">911,868&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;22</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i23d5469e701244a891cca7da0be968f5_43"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:21.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended <br>September 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br>September 30, 2020</font></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,430.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,421.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,326.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(126.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,199.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">174.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(174.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">101.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(635.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">628.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">158.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(149.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">135.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">158.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">293.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">228.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">226.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,110.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">653.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,763.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,208.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">80.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,289.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company&#8217;s non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company&#8217;s reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company&#8217;s ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;23</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the three months ended September 30, 2021, include the following&#58; </font></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">IPR&#38;D</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of Debt </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(v)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(9.0)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(174.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(174.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">628.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">158.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">149.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">176.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">320.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(101.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">653.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.72</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to business development transactions with Protomer Technologies Inc., Kumquat Biosciences Inc., Lycia Therapeutics, Inc., and ProQR Therapeutics N.V. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude charge related to the repurchase of higher-cost debt.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.86pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude partial reversal of COVID-19 antibodies inventory charge. </font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;24</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the three months ended September 30, 2020, include the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.251%"><tr><td style="width:1.0%"></td><td style="width:38.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.405%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(126.5)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(126.5)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(101.4)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(149.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(149.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(1.9)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(117.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">98.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">80.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.09</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily severance costs incurred related to restructuring.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;25</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i23d5469e701244a891cca7da0be968f5_46"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br>September 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br>September 30, 2020</font></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,262.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(771.4)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,491.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">3,763.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(287.9)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:right;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3,475.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">498.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(498.3)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">294.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(294.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">211.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">161.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(161.3)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(124.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">156.6&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">694.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(814.7)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(119.8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">460.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">324.6&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">784.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">683.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(77.8)</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">606.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">3,855.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,313.3&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,168.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">4,076.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</font></td><td style="border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,083.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">4.23</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</font></td><td style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">4.47</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4.48&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company&#8217;s non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company&#8217;s reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company&#8217;s ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;26</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the nine months ended September 30, 2021, include the following&#58; </font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">IPR&#38;D</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of Debt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(v)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(395.0)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(376.4)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(771.4)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(498.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(498.3)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(211.6)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(248.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">156.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(48.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">114.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">324.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">313.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">405.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(199.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">320.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">474.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,313.3</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.44</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to business development transactions with Rigel Pharmaceuticals, Inc., Precision Biosciences, Inc., Protomer Technologies Inc., Kumquat Biosciences Inc., Merus N.V., Lycia Therapeutics, Inc., ProQR Therapeutics N.V,  MiNA Therapeutics Limited and Asahi Kasei Pharma Corporation.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Excludes charge related to the repurchase of higher-cost debt. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.86pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Excludes primarily the net inventory charge related to COVID-19 antibodies, an intangible asset impairment resulting from the sale of the rights to QBREXZA, and acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc. </font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;27</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the nine months ended September 30, 2020, include the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">IPR&#38;D</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total </font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(283.7)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(287.9)</font></td><td style="background-color:#ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(294.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(294.1)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(161.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(161.3)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(814.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(814.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(171.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(77.8)</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">224.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">269.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(643.6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">156.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.01</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. These costs were related to both a business development transaction with a pre-clinical stage company as well as business development transactions with Sitryx Therapeutics Limited, AbCellera Biologics Inc., Evox Therapeutics Limited, and Junshi Biosciences Co., Ltd. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude gains and losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily severance costs incurred related to restructuring, as well as acquisition and integration costs as part of the closing of the acquisition of Dermira, Inc. </font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;28</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20211026.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8b4c3870-ed11-4d50-86ca-c3b6190d30cd,g:830a719d-b847-408f-9e26-fd7970cff3e0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20211026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20211026">
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211026_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.000NotesDueJune22022Member" abstract="true" name="A1.000NotesDueJune22022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20211026_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8b4c3870-ed11-4d50-86ca-c3b6190d30cd,g:830a719d-b847-408f-9e26-fd7970cff3e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20211026.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i3fcb08a7b5ea493ba3367c1a09cff0d9_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eb6be5a3-7817-4ff2-af04-693bf7800496" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_DocumentType_eb6be5a3-7817-4ff2-af04-693bf7800496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_50e019ac-2d05-4bd5-8f07-e3f75a61cdab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_DocumentPeriodEndDate_50e019ac-2d05-4bd5-8f07-e3f75a61cdab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_717cf921-1c85-45ab-964c-fbff83b24629" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_717cf921-1c85-45ab-964c-fbff83b24629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c92009de-c507-4a8b-b8ba-5457bc8b3ca5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityFileNumber_c92009de-c507-4a8b-b8ba-5457bc8b3ca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3ea4d81f-536a-4199-9718-1db9309562df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityTaxIdentificationNumber_3ea4d81f-536a-4199-9718-1db9309562df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1b191583-8e8f-4d47-90b0-f7d3091f1132" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressAddressLine1_1b191583-8e8f-4d47-90b0-f7d3091f1132" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0dc7d2b0-dd31-4400-8e34-cdfd1f971595" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressCityOrTown_0dc7d2b0-dd31-4400-8e34-cdfd1f971595" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3ab3a96b-a523-4505-b031-425425322faa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressStateOrProvince_3ab3a96b-a523-4505-b031-425425322faa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_54a626d9-3a0e-457f-b2e4-d9f38cfa017c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressPostalZipCode_54a626d9-3a0e-457f-b2e4-d9f38cfa017c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55525c03-3d55-444d-bfb9-e4596b7f6028" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_CityAreaCode_55525c03-3d55-444d-bfb9-e4596b7f6028" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c93c6eea-36c9-4b0c-baf3-f236f8df61ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_LocalPhoneNumber_c93c6eea-36c9-4b0c-baf3-f236f8df61ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_38180567-5bb5-454f-9986-ded7945b49fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_WrittenCommunications_38180567-5bb5-454f-9986-ded7945b49fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_cb15f5a7-ef99-4ccd-9973-e8405f88884f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_SolicitingMaterial_cb15f5a7-ef99-4ccd-9973-e8405f88884f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_27450d2d-412b-44f2-9896-c6e46fa670b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_PreCommencementTenderOffer_27450d2d-412b-44f2-9896-c6e46fa670b7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_712fae12-8abe-4a38-99d6-17f8a9ea402d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_712fae12-8abe-4a38-99d6-17f8a9ea402d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d99a857e-b385-4ac2-87b8-8d119b6b3014" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityEmergingGrowthCompany_d99a857e-b385-4ac2-87b8-8d119b6b3014" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f3c66f41-fe57-4fce-be9c-44637e01796e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_Security12bTitle_f3c66f41-fe57-4fce-be9c-44637e01796e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1fc0b5b7-fd4c-460f-9d4e-1d9b57ffbdbe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_TradingSymbol_1fc0b5b7-fd4c-460f-9d4e-1d9b57ffbdbe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_003f31a7-09cf-489c-b61c-41849d22487e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_SecurityExchangeName_003f31a7-09cf-489c-b61c-41849d22487e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df9a2477-ff4c-4fb0-a4d3-9303cad00389" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityRegistrantName_df9a2477-ff4c-4fb0-a4d3-9303cad00389" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_efbe2848-7624-46b1-92ea-91155ba42f06" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityCentralIndexKey_efbe2848-7624-46b1-92ea-91155ba42f06" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e9e81065-b016-4612-9b71-1dc9502b875b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_AmendmentFlag_e9e81065-b016-4612-9b71-1dc9502b875b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ceb5b7e-9968-4518-bef2-f9254c1b9492_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:to="loc_us-gaap_ClassOfStockDomain_4ceb5b7e-9968-4518-bef2-f9254c1b9492_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:to="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_16b3e0b7-2e03-45e8-96cf-407579e01339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_us-gaap_CommonClassAMember_16b3e0b7-2e03-45e8-96cf-407579e01339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_83506a24-136f-4cf6-bbb9-07d640a5112c" xlink:href="lly-20211026.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1.000NotesDueJune22022Member_83506a24-136f-4cf6-bbb9-07d640a5112c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_37573adb-922b-43f6-9b0e-a090bde680db" xlink:href="lly-20211026.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A718NotesDueJune12025Member_37573adb-922b-43f6-9b0e-a090bde680db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_50c3be0c-a393-4c60-86c1-52c66f5289ce" xlink:href="lly-20211026.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1.625NotesDueJune22026Member_50c3be0c-a393-4c60-86c1-52c66f5289ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_3a71a837-efba-4de1-997f-f7f97458ca57" xlink:href="lly-20211026.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A2.125NotesDueJune32030Member_3a71a837-efba-4de1-997f-f7f97458ca57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_5764ee98-97a4-42ab-846c-47b5e73e1a85" xlink:href="lly-20211026.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A625Notesdue2031Member_5764ee98-97a4-42ab-846c-47b5e73e1a85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_00811434-4d0d-4b7a-a917-2633db263d73" xlink:href="lly-20211026.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_00811434-4d0d-4b7a-a917-2633db263d73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_82ed841f-b5d8-4f53-852f-dc70a46957d6" xlink:href="lly-20211026.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1.700Notesdue2049Member_82ed841f-b5d8-4f53-852f-dc70a46957d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_8f2b6786-2124-47e5-afba-d2a588ab5b89" xlink:href="lly-20211026.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A500NotesDue2033Member_8f2b6786-2124-47e5-afba-d2a588ab5b89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_3b08a3b4-1b60-4180-9cef-22eb80d7d104" xlink:href="lly-20211026.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1625NotesDue2043Member_3b08a3b4-1b60-4180-9cef-22eb80d7d104" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_77e893ce-f0e2-4ea8-b84b-9932573e0c36" xlink:href="lly-20211026.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1125NotesDue2051Member_77e893ce-f0e2-4ea8-b84b-9932573e0c36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_1d5bea98-3b55-4d4f-9861-cf2c399e1010" xlink:href="lly-20211026.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1375NotesDue2061Member_1d5bea98-3b55-4d4f-9861-cf2c399e1010" xlink:type="arc" order="11"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20211026_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8b4c3870-ed11-4d50-86ca-c3b6190d30cd,g:830a719d-b847-408f-9e26-fd7970cff3e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_5b75af64-54dd-4c4d-90e8-32bb7bc219c4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_f1684846-2e2c-44b2-b73f-f28fac26e5e4_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20211026.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_f1ab8d8e-c305-441e-82c8-6f9b6fb9b2ca_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20211026.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_c4c457fd-0489-4978-9fa9-8866cd7d368f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_d9f97bc1-69dc-46e0-adc0-e7887ea1dae9_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20211026.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_71e865c7-1742-4df3-a719-c9f33d586afe_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5c5b9ab3-5cfb-4f01-87f9-60a8c8317f94_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_4f2f6e65-0237-4870-80ef-d995336ae04b_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20211026.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b3bee753-f339-4295-bbc3-402e6b2009c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_37b4a52c-37fb-47e7-bda8-7d1069e204a6_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4b1ea0a6-1958-4965-a3ad-e260d3aaec14_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_9c77ed39-7bd8-4504-881f-badaa741450b_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20211026.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_c886ffb7-ffb5-44d7-a89a-52529af22adf_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member" xlink:href="lly-20211026.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member" xlink:to="lab_lly_A1.000NotesDueJune22022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_15f9119c-55c2-4554-89e2-ff9ce7ba4738_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_ab113808-1683-4a1a-bb07-b68a90c3a4d0_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20211026.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_4a52907b-844d-4185-94f6-94bb2ec54202_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_965e4421-d315-4ef4-a8ab-dd6306219dce_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20211026.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1b69fc6d-2b94-49ef-bf2d-052e530d59e9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_5286e554-c736-4bfc-a8ac-9270bec31397_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20211026.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e33b0593-0346-471f-b30b-a26d328bd6f1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_936612dd-e1c4-427b-ab67-551137fa756e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_57e436ff-6972-4c9a-b208-ac02fc136e48_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1e9871b4-6839-427a-934e-2fa3b893bae5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_2f2f67e9-a02e-4e15-8ee7-2f531558b3f4_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20211026.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_65eb4f92-170d-403c-9620-e6444e26aafd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4c398f46-48db-4f53-bfe7-14498f0a38f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_03250649-f27a-4dcb-8794-0fdd3ff35819_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_43f11bf5-e18f-4228-9105-95002b82709f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2a330786-c939-4e6b-89ee-484cfa9e806e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c9732982-164f-4da8-96aa-b174118432f4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6607f2b0-95fc-4246-a474-ee2a81b4217d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a22f5482-a66b-47a7-bd04-0b09255cf079_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b2cd388f-ceb8-4715-a568-2b7111757c33_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_8485f5c8-468f-44d4-93f8-4b72bacafa29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a4ee1676-c1bc-421b-8db9-01c2ff5021a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_c03b33cd-1dc6-4319-b653-f86113bc573e_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20211026.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4d6b0955-3d2b-4eb6-96e4-f7624f3716bb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_39d37746-173a-4d7d-a334-3eeeb614f037_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_191ab0f3-c02b-4cb1-9b1f-61a74f69cec7_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20211026_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8b4c3870-ed11-4d50-86ca-c3b6190d30cd,g:830a719d-b847-408f-9e26-fd7970cff3e0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20211026.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4e5c3c5d-6913-4faf-b8b1-dfbd49dcc11b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e5c3c5d-6913-4faf-b8b1-dfbd49dcc11b" xlink:to="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4ceb5b7e-9968-4518-bef2-f9254c1b9492" xlink:to="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_16b3e0b7-2e03-45e8-96cf-407579e01339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_us-gaap_CommonClassAMember_16b3e0b7-2e03-45e8-96cf-407579e01339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_83506a24-136f-4cf6-bbb9-07d640a5112c" xlink:href="lly-20211026.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1.000NotesDueJune22022Member_83506a24-136f-4cf6-bbb9-07d640a5112c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_37573adb-922b-43f6-9b0e-a090bde680db" xlink:href="lly-20211026.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A718NotesDueJune12025Member_37573adb-922b-43f6-9b0e-a090bde680db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_50c3be0c-a393-4c60-86c1-52c66f5289ce" xlink:href="lly-20211026.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1.625NotesDueJune22026Member_50c3be0c-a393-4c60-86c1-52c66f5289ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_3a71a837-efba-4de1-997f-f7f97458ca57" xlink:href="lly-20211026.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A2.125NotesDueJune32030Member_3a71a837-efba-4de1-997f-f7f97458ca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_5764ee98-97a4-42ab-846c-47b5e73e1a85" xlink:href="lly-20211026.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A625Notesdue2031Member_5764ee98-97a4-42ab-846c-47b5e73e1a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_00811434-4d0d-4b7a-a917-2633db263d73" xlink:href="lly-20211026.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_00811434-4d0d-4b7a-a917-2633db263d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_82ed841f-b5d8-4f53-852f-dc70a46957d6" xlink:href="lly-20211026.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1.700Notesdue2049Member_82ed841f-b5d8-4f53-852f-dc70a46957d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_8f2b6786-2124-47e5-afba-d2a588ab5b89" xlink:href="lly-20211026.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A500NotesDue2033Member_8f2b6786-2124-47e5-afba-d2a588ab5b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_3b08a3b4-1b60-4180-9cef-22eb80d7d104" xlink:href="lly-20211026.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1625NotesDue2043Member_3b08a3b4-1b60-4180-9cef-22eb80d7d104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_77e893ce-f0e2-4ea8-b84b-9932573e0c36" xlink:href="lly-20211026.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1125NotesDue2051Member_77e893ce-f0e2-4ea8-b84b-9932573e0c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_1d5bea98-3b55-4d4f-9861-cf2c399e1010" xlink:href="lly-20211026.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_76934ce9-d9e6-47fa-88fd-29f8ba4f90b9" xlink:to="loc_lly_A1375NotesDue2061Member_1d5bea98-3b55-4d4f-9861-cf2c399e1010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_b4fe1215-54a4-49a7-84a0-6222485addd7" xlink:to="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eb6be5a3-7817-4ff2-af04-693bf7800496" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_DocumentType_eb6be5a3-7817-4ff2-af04-693bf7800496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_50e019ac-2d05-4bd5-8f07-e3f75a61cdab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_DocumentPeriodEndDate_50e019ac-2d05-4bd5-8f07-e3f75a61cdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_717cf921-1c85-45ab-964c-fbff83b24629" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_717cf921-1c85-45ab-964c-fbff83b24629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c92009de-c507-4a8b-b8ba-5457bc8b3ca5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityFileNumber_c92009de-c507-4a8b-b8ba-5457bc8b3ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3ea4d81f-536a-4199-9718-1db9309562df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityTaxIdentificationNumber_3ea4d81f-536a-4199-9718-1db9309562df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1b191583-8e8f-4d47-90b0-f7d3091f1132" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressAddressLine1_1b191583-8e8f-4d47-90b0-f7d3091f1132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0dc7d2b0-dd31-4400-8e34-cdfd1f971595" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressCityOrTown_0dc7d2b0-dd31-4400-8e34-cdfd1f971595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3ab3a96b-a523-4505-b031-425425322faa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressStateOrProvince_3ab3a96b-a523-4505-b031-425425322faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_54a626d9-3a0e-457f-b2e4-d9f38cfa017c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityAddressPostalZipCode_54a626d9-3a0e-457f-b2e4-d9f38cfa017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_55525c03-3d55-444d-bfb9-e4596b7f6028" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_CityAreaCode_55525c03-3d55-444d-bfb9-e4596b7f6028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c93c6eea-36c9-4b0c-baf3-f236f8df61ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_LocalPhoneNumber_c93c6eea-36c9-4b0c-baf3-f236f8df61ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_38180567-5bb5-454f-9986-ded7945b49fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_WrittenCommunications_38180567-5bb5-454f-9986-ded7945b49fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_cb15f5a7-ef99-4ccd-9973-e8405f88884f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_SolicitingMaterial_cb15f5a7-ef99-4ccd-9973-e8405f88884f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_27450d2d-412b-44f2-9896-c6e46fa670b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_PreCommencementTenderOffer_27450d2d-412b-44f2-9896-c6e46fa670b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_712fae12-8abe-4a38-99d6-17f8a9ea402d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_712fae12-8abe-4a38-99d6-17f8a9ea402d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d99a857e-b385-4ac2-87b8-8d119b6b3014" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityEmergingGrowthCompany_d99a857e-b385-4ac2-87b8-8d119b6b3014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f3c66f41-fe57-4fce-be9c-44637e01796e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_Security12bTitle_f3c66f41-fe57-4fce-be9c-44637e01796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1fc0b5b7-fd4c-460f-9d4e-1d9b57ffbdbe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_TradingSymbol_1fc0b5b7-fd4c-460f-9d4e-1d9b57ffbdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_003f31a7-09cf-489c-b61c-41849d22487e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_SecurityExchangeName_003f31a7-09cf-489c-b61c-41849d22487e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df9a2477-ff4c-4fb0-a4d3-9303cad00389" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityRegistrantName_df9a2477-ff4c-4fb0-a4d3-9303cad00389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_efbe2848-7624-46b1-92ea-91155ba42f06" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_EntityCentralIndexKey_efbe2848-7624-46b1-92ea-91155ba42f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e9e81065-b016-4612-9b71-1dc9502b875b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_120a66d5-1e46-4729-8e5f-67afd1e0f5fe" xlink:to="loc_dei_AmendmentFlag_e9e81065-b016-4612-9b71-1dc9502b875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logoa31a.jpg
<TEXT>
begin 644 logoa31a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
MX)O_ !%_;\\<K;>%-+:S\.VMR(=6\2WH"Z?I_0G'_/:7 SY4?/SIGRX_WE?H
M=^P]_P &V6D^&'L]:^.6N_V]= B8>&M'N)(;,=<_:;CAY.WR1[,%!^\<9%?I
MM&G@W]G7X;6]NO\ PCO@GPEH-OY40_<Z9INGQCL/NQQK]*^GPO#6+QU3ZUFT
MVEVZV_**/P?/_&OA[AC!?V#X?8=3EMSJ+Y%+175_>JROU;M>VLH^Z>4_L+_\
M$]/ /_!/SX9-HOA>U^U:OJ0#:SKUV,WNKS#GG&?+B'\$*<#J<N7D?Z.KF?!/
MQ!T7XD>%K?5O#NN:9X@TNZ'[B^L+B.ZAF'M)&2OY5TU?H%"C2I4U"BDHK:VQ
M_)&;9ECL?C*F+S*<IUI.\G*][^=]5;HMDK)605^:?_!9?_@LLO[*VF77PX^&
M=U;77Q&NX#_:&H ^;#X9B?CMP]T>PZ1CDY/%>E?\%D?^"F-I^P9\%6TK0;JW
M?XH>,898-'C9!,-(A^Z]^Z$8^3CRU;AY,\.D<@'X/_!3X->,_P!L;X]:;X9\
M.VMYKOBKQ5J.6FN)GER7.^>>67G]V,O)(Y]Z^0XES^5&2P.#UJ2W:W5^B\W^
M'S/Z)\#_  DPV8TGQ3Q(E'!T[N,9:*?+?FG+I[.-NOQ/R7O7/@5\!O'7[9_Q
MOM?#'A:SN_$7BW7)YKVZN9II#@>9F>[N)VR53+_.[\DOCEWY_<3]E;_@G]\'
M_P#@CM\ =4^(WBR\L]4\3:+8?:-7\37$(\R#.$^S649/R!W<(H_UDCR =-D:
M>G_L)_L(> O^"9O[/]Q;6MQ;2:E) M]XI\3WRK UR8TWO([O_JK>/YMB9P@R
M3\Y=S^0?_!9;_@JK<?MU?$=O"?A.YNK/X7^&;H_8 V8F\0W8RGVR1/X(N3Y<
M9Z(=[X=_+C\RG@Z&28?ZUB;3KR^%/6S_ ,EU9]IC.)<U\4L[>0Y&Y4,JI6]K
M->ZYQ6EG:UN9*T(?]O26EE\P?M1?'[6_VN?VA_$WC[6+?_B8>+]2^T"V@'F_
M9XN(X+=/[^R-(T_X!7]#7_!)G]DF7]C7]B'PGX9U*U6U\3:CG6M>7'S"\N0G
M[MQ_?AB2& _]<>*_-?\ X-__ /@FA)\9_B+:_&SQIII_X1'P?<Y\.VUQ#\NK
MZC'C_20?XHX&'4?\MQU_=O'7Z#?\%6_^"G>A_P#!/7X1,ME]GU3XC>)('30-
M)9CY<'4&]N>X@C/1!S(_R @>9)'MPSAXX:E4S?&NW-?5]F[M^KZ(\_QMSR>=
MX_">'/"]/F5)QYE';FC'EC"^RC3BVY-NR;ULXNW6?MX?\%*_AU_P3[\%K=^*
MKIM5\1:E ?[(\/V#)]MU C(+GM#"".9'.#@A!(_R5^*G[7'_  6N^/'[5FH7
M5O#XFO/ 7ALMNM]*\,W#V96+G_73_P"OFX^^/,$9Q]Q.:\(DE^(W[<G[1/S?
MVMX^^(GC?4>/^6UQ=S_I''%'&/\ 82-$_@C3C]EOV1_^"3'PA_X)G_!:]^*?
MQ@72_%?C#0;!M1U#4+J(3Z=H>P[Q':02#$DF_8B2.#(\@7RPA?:>>6/S#.:C
MCAW[.C'=[67F^NG1/2^I[6'X5X.\,,'2J9O36.S*K;D@DI-R;2M"$KJ*YG93
MDG.3^'>Q^&=EXIU*V\3#68-2O+?4A<^>-0%P_P!H\W_GIYGWZ_H3_P""&7[5
M'BS]J+]AJSU3QI>7FJ:UX8UFX\.MJ%RWFSW\*1P3Q/*Y^^X2=8]_5RGS_/FO
MP5_:4^--Q^T1\?/&7CBYMC:GQ1JUQJ9M_P#GWBDD/EQ_]LTPE?T5?\$H/V7;
MC]D#]A;P/X3U2U6R\130-JFLPLHW0W5TV\QO_MQIY<)_ZY5CP73FL?4<&W!)
MW??6R^_<]+Z36(PG^JV$6+I1CBISBXK1N"4;U$I63Y5=1>R;:=M%;Z?HHHK]
M./X5"BBB@ HHHH **** "BBB@ HHHH **P?&/C31_!6D_:]:U+3M)M>\UY<I
M#&#]6XKC]'_:W^%?B'4OLMC\3_A_>72C_4V_B"SED_(.36<JL(Z2:7S.JC@<
M36BYT:<I);M1;7WI6/3J^)?VKO\ @A5\!?VHM1FU.'0[KP#X@NL2W&H>&C':
MQW/!'[RW='@]\HB2?[=?:-E<PWL(GA93&1UJS6>*P=#$1Y*\5)>?]7._).(L
MTR:O]9RK$3HS[Q;5_)K:2\FFC\3?BI_P:T^-=+"_\(7\4/"NL=]NL:=<::1_
MP*'SZ\WU'_@VK_:"TU_WFK?#(PVXSYW]KS^5C_@=K7[]5^-O_!>/_@K>FLC4
M_@1\,]2WV^3;>+M6MIL>?V?3HW_N <3G_MGT\P'X[.,BRC!T'7J1:[)/=]E>
M_P _(_I/PX\6/$;B7,X95A*D)]9U)4U[D+ZRER\J\DDDV[+K=?E/XP\+_P#"
M(>,=1TR/4M)U3^S[F6#^T+!GFL[C8_\ K(7=$WQ^AKZ8_P""4_\ P3%U/_@H
MK\5+JWO;B^T+X?\ AN -J^K0*AE\Y_\ 5V\)?CS9.7/!$<:<_?3?X_\ LD?L
ML^*/VS/CKH/@'PE:;]4U-_\ 2+GEH=/M4_UEQ/C[L<?\]B#YW3/]*'[(_P"R
MOX6_8U^!>A^ O"5ILTW3!NN+@E?.U&Y?!DN9SW=SZ=!L081!7SG#.0_7:SK5
M5^ZB_O?;T[G[%XX>*[X6RV.68"HGCJJ5G9?NX]9M;<S::BFK7O+515_!?@/_
M ,$%_P!G+X$F"XG\+7?C;4K/E;GQ-?&\'XP((X'_ .!QFOKSPEX4TOP-H%OI
M6CZ;9Z3IMHOE06UE D,, _V$3A17045^I8? X?#JU""CZ*WX[_>?P;GG$V;9
MS5]KFN)G6?3GDY6]$W9>22T"OP>_X.6?B=XLU;]LS0?">H3W,?A/3_#T%[I=
MBK?N+F6:2<27'^_^[V?]LJ_07XK?\%O?@S\&_P!KVW^%NIZI=/;VH:VU?Q+#
MB73-(U#^&VE.,D<.)'3_ %<A1#D^9Y?L7[3W[&?PG_;R\&:.GCC0;/Q59VP^
MUZ3J%M<O%-#YBCF*>%P?+<!25SY;X4X->/G%&&:86>&PE1.46KZ]NC/T?P\Q
M]?@7/<+G?$&"G[&K"7(^76TEI."=DVENFT^65]FK_D'_ ,&W/Q$\3:7^W)<^
M&M-N+J3PWKV@74^L6N?W*B#RS#<[/[X=T3=Z3FOVY^.'Q@T']GWX5Z]XU\1W
M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
M3608,AZ)&^2?WB));_X)9_\ !(?Q=^WYXCM]<U877AWX8:9<;+_5BO[[4"GW
M[:S#??D]7_U<?/WS^[K]_/@O\&O#O[/WPXTGPCX3T>TT/PYH4/DVEC ORP<Y
M)SU=G<EV=\N[N7))S7?E.4XC-L1_:&/^#HMKKHDND?S/EN/O$+)_#_*/]4>#
M[?6$K3FK/D;6LI/[55[)?8LN9:*)S?QD^)_@W]A/]EK5/$-Q96VD^$? >E8M
M;"W(B#!!Y<%K#G^*20QQI[N*_FI_:)^/7C']M7]HC5O%FO/=ZIXF\4:@(;;3
M[??-]FW2;(K2&/KL3*(@'7.?]8_/Z'_\',?[7Q\0_$+PS\%-(NU6TT&W&MZ^
M!T-U(,6L3GUC@,DG_;=*PO\ @WW_ &,=%_M'7/VBOB$MII?AGP(TL.CSWY\F
MS^U(G^D7KE_DV01OLC?IYCR'AX:6>5IYEF$<LH:0COVTW?HELO7N8^%67X7@
MK@^MQQFD7/$XCX$_B:;M"*>KO5E[[>ONVE;W=?MS_@D5_P $QM#_ .">WP8/
MB;Q4+3_A8^N6(EUK49F3RM%M<"3[%&X^1$3@R/\ QNG]R-,?G+_P6O\ ^"LC
M?MC>-6^'W@*Z;_A5_ANYS/<+T\1W2$C[1_UPCSB-.Y^<\^7Y>E_P5Q_X+67W
M[6JW/P]^%]U>:3\-1^XU'4/G@O/$_P!4^_'!U_=\._\ &!_JZX/_ (),_P#!
M(WQ#^WIXTM?$WB);S0_A;I=Q_I6H+^ZN-9E3_EWM?R(D?_EGSUDZ9X[&?6.7
M)LH7N=6NO>[[=WU/4X1X7EE$JOB3XBU+5W[T(/7V=_A2CK[]O=A!? KN3YKN
M/IG_  02_P""9<W[0GQ.M/B]XRTN0>!?!UUYND6UP,CQ!J"?Q?[4$$@#D]'?
M8F9!'(!^\%<SX!\!Z'\,/!6G^'?#NGVND:+HMNMG8V-NOEQ6T2# C0>@%5=9
M^)/ASP]XLTG0]2U[1[/7O$ F_LJQFNHX[K4?) >7R8\[Y-@QNV9P.M?;9/E5
M++\.J,7J]WW?^1_+GB+QYCN,<YGF%6+4(IJG!:\D%=ZVNKOXIO\ **5NPHHH
MKUC\^"BBO"_@+^W9\*?VF_B'XD\*>"_&^DZ[K7AF9H;FW@8[IU39NFA)_P!=
M"&;89(_DSWPZ$YRK0C)1DTF]O/T.O#Y?BJ]*I7HTY2A32<VDVHINR<FE9)O:
M]K]#W2BBBM#D"BBB@ HHHH *_*?_ (+._P#!:76?V>?&EY\*/A+=PV7B>Q$7
M_"0:\]OYO]G%UW_9;8/^[,I1H]\G(CW;!\^3'^K%?RO_ /!0C2M0T?\ ;U^,
MUOJ@N/[0/C#6)LRGM)>2/&_^X8W0C\*^3XNS&MA<+&-!\KD[7[)+]3^@OHZ\
M%Y9GV?U*F:152-""DH/52DVDFUU4=[;-VOIH^;BTSXG_ +7OQ$N[B&U\=?$S
MQ,1F<B&ZUB[,?O\ ZR3%=%XH_P""?7QR\(Z;]IU3X._$RSM<>;YY\+W?E#_?
M/E_)7Z[_ /!#3]L'X$^&OV/_  SX(T[7/"W@SQQ;M,VNZ=?W45G=ZM=;WS<(
M\F/M.8PF-I/EHH3I'Q]V^)/VBO /@S2/M>L^.O!VCVH_Y;7NL6\,?_?;OBO!
MP/"N'Q.'6(J5]9*[>FE^COK<_6N*?I 9UDN<5,HPF4VITY.,5+F3DD[)Q44D
MHNUU9/3J?R^_!?\ :<^)'[,7B'[5X%\8^*/"=T+C,]MI^H20PW$O_3:#_5R?
M]M$-?H_^Q+_P<J:SI&HV^B_'315U*Q_U)\3:3;^1>1'IOGM1^[?W,'EX XC<
MUZW_ ,%.OVU?V'_BEH=Y;^+K>Q^)?BKR0+;4/"-N/[1MNOEXU+Y(?+&.4\R3
MK_JWZ5^)>L26LNH7(L[>[M=/\[]S#/-YT@C_ (-SA$WM_P  2O)K5L1D]91P
MN(4UV3NOFM5]S9]]E>5Y1XCY;*OG^33PM33WY149.Z^*%1*,VEUYHJ+TT?3]
M<O\ @K9_P7GL-5\,W7P^^ VJ-<G4;?&L^+[??%]GC=/^/>R/#^9C[\P \OHG
M[SYX_P L_@A\#_%7[2/Q4TOP7X/TVZU3Q%K$_DP01=%'\<LAQ\D:<EW/85Q=
M?KC_ ,$3OVZ?V6_V:OAZNB:NU[X*^)&I8_M;7=<A\ZWU%O\ GG!<1I^Y@'79
M(B<]7D(S4T\1+.,<OKM10CTZ)+LNEWYL[,9E%+PVX6G#A?!3Q%5[M+FE*5G[
M]3EM)QBME%65K>ZFY+[O_P""9W_!.?PW_P $]?@FNFV;6^J^+M<$<WB'5_+Y
MNI@,B*/H5@CZ(/<OU<X^J*\NT3]L+X3^*='_ +2TWXF_#^\L"/\ CX@\16LD
M/XL'KP[]HC_@MM^SO^SWIS?\5[8^-=29,V]AX7/]K-.?^NZ'R%_X'(*_4X5L
M%A*,8J<8P6VJ/X+Q&5\3\19I4KU,/5KXBI*\O<DW?ST2C%;):)+8^OI9Q /G
MK\>_^"N__!>*"[T_4?AM\"M;4_:#]FU;QAI\W;^.+3Y!WZ?Z2/\ MGVD'RS_
M ,%"?^"UWQ._;B-YX:TUE\"?#VZ)7^R=/N2;C4(NQNI^#)G'W$V1\_Q\/7QG
M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>lly-20211026_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20211026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20211026.xsd" xlink:type="simple"/>
    <context id="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="ie995d89d5c494c239211a78a6682af37_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i37f68d019fc444398a863e31316ec594_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="i014ec31d847549518d3d26c2b459250e_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-26</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF80L2ZyYWc6MzdkMDcyNzA4NDFhNDcyMWI1ZDExYmNjYWQyZGIyMmMvdGFibGU6MjVkNDM5MDg5MTNmNDdmNjhjNmJiY2FiYmRhNmQzMzgvdGFibGVyYW5nZToyNWQ0MzkwODkxM2Y0N2Y2OGM2YmJjYWJiZGE2ZDMzOF8yLTEtMS0xLTE_c6cffe31-ec6e-4d11-8ca4-a3a8bbbb807a">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF80L2ZyYWc6MzdkMDcyNzA4NDFhNDcyMWI1ZDExYmNjYWQyZGIyMmMvdGFibGU6MjVkNDM5MDg5MTNmNDdmNjhjNmJiY2FiYmRhNmQzMzgvdGFibGVyYW5nZToyNWQ0MzkwODkxM2Y0N2Y2OGM2YmJjYWJiZGE2ZDMzOF81LTEtMS0xLTE_fa4d1695-b983-401c-b307-362ba14bb789">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg1_130b7be1-99ae-4aeb-b966-80a8ffe6bbae">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xNTk_c8c3b0ff-1444-40d0-81d7-6d3f567140cc">2021-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg2_685a63f9-e991-4e60-b865-0ae69d516235">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ODNiMDNlNDA1ZWIwNDIxMTgxMDcwMWU0MDQ0NTI3NTIvdGFibGVyYW5nZTo4M2IwM2U0MDVlYjA0MjExODEwNzAxZTQwNDQ1Mjc1Ml8wLTAtMS0xLTE_f3fdcec2-69db-4d68-bb70-e99cb5445ec9">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ODNiMDNlNDA1ZWIwNDIxMTgxMDcwMWU0MDQ0NTI3NTIvdGFibGVyYW5nZTo4M2IwM2U0MDVlYjA0MjExODEwNzAxZTQwNDQ1Mjc1Ml8wLTItMS0xLTE_f6a04847-8152-4138-911e-7346d721f933">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ODNiMDNlNDA1ZWIwNDIxMTgxMDcwMWU0MDQ0NTI3NTIvdGFibGVyYW5nZTo4M2IwM2U0MDVlYjA0MjExODEwNzAxZTQwNDQ1Mjc1Ml8wLTQtMS0xLTE_6a4ed9b5-9532-4aee-b942-c85c7f4a9d78">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8wLTAtMS0xLTE_ca3d0b97-9a43-4d90-b025-7ece79c76d4d">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8xLTAtMS0xLTE_3ec89721-3629-4810-94f8-12039d10c548">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8xLTEtMS0xLTE_02d0b1cc-0c02-47c9-95ce-e756b29b9a55">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjdlODFjNzljMGRhNDE0NGI4Yzk3YWI3YzUxNjFkNGQvdGFibGVyYW5nZTpiN2U4MWM3OWMwZGE0MTQ0YjhjOTdhYjdjNTE2MWQ0ZF8xLTItMS0xLTE_5e6ad306-5216-4fec-8fb8-61b2621ce0ea">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg3_4e80422e-d2a6-4a89-b6aa-c12ecfd1ea78">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg4_3924a600-1729-4f22-b80e-731c9ac78fc8">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YjY4MGQ3NjBmZDZjNGNkMjkyZWE1NWE4Y2YzMzM1OWEvdGFibGVyYW5nZTpiNjgwZDc2MGZkNmM0Y2QyOTJlYTU1YThjZjMzMzU5YV8wLTAtMS0xLTE_181f1f20-29e3-4b85-b771-ec8692b92fce">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6MTU5YTk4ZmNhYjc3NDYxYzhmZWIyYmZkMzM1MmFmN2UvdGFibGVyYW5nZToxNTlhOThmY2FiNzc0NjFjOGZlYjJiZmQzMzUyYWY3ZV8wLTAtMS0xLTE_1e03e2b1-4a24-4929-9a6f-fa6cc690c42d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6ZWZmODhjODViNmFmNDY3Yzg0MWU4NTc1MTEyYjBhMDEvdGFibGVyYW5nZTplZmY4OGM4NWI2YWY0NjdjODQxZTg1NzUxMTJiMGEwMV8wLTAtMS0xLTE_29aba61b-b8a4-4a39-aa02-fd35f4bdd490">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6OTRhMTkxYzkxNDZhNDFmYWJiMDEzNGE1ZjkzZTI3ZjYvdGFibGVyYW5nZTo5NGExOTFjOTE0NmE0MWZhYmIwMTM0YTVmOTNlMjdmNl8wLTAtMS0xLTE_3a4086dd-1d7e-4503-b4e4-c7405f8ea401">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xLTAtMS0xLTE_03b4b0f4-671d-41e0-a658-65cff62f9552">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xLTItMS0xLTE_6af81dc6-ddaf-4f12-9658-af0c3d94e2b1">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia1d8ad6eeb0e4e8bb5020a1dd8982624_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xLTQtMS0xLTE_8c3ecff4-69fb-49b5-b8b8-625bffe35d5e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8yLTAtMS0xLTE_9d77ba04-d9db-4f33-9a4f-6d2bf77afacc">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8yLTItMS0xLTE_fb1bcc66-d82c-443f-856f-5550532513fd">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i637e3654ea0847f38976c5ea0910097a_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8yLTQtMS0xLTE_decca609-e594-4e4f-bebb-2bf6336934d9">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8zLTAtMS0xLTE_3659520d-e859-44d7-8aba-d4841ac628e5">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8zLTItMS0xLTE_78a0dded-9d92-431c-add4-bd72d4089b12">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i32bbba4c7db94f1dbe5f2913e1224dd2_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8zLTQtMS0xLTE_2a4b07d2-b437-463b-bca4-4d3d9a263989">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF80LTAtMS0xLTE_463c8308-be9b-41a6-971f-89c74eaf1693">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF80LTItMS0xLTE_04d16166-c797-4620-9651-906ada3e56e6">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6d0fff600fd24496aa6f4e597dd67c29_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF80LTQtMS0xLTE_c3dc6166-d480-4690-87ec-8d85ee672df8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF81LTAtMS0xLTE_19cac08e-4f03-45fd-b38c-b58807fab668">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF81LTItMS0xLTE_7d6ae5de-4230-4eba-a98b-580fe930eee8">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icb857eaf00db4efcb2441b7e79c37e99_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF81LTQtMS0xLTE_66c31916-e09d-4924-967b-4be00e8f06a7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF82LTAtMS0xLTE_7a0be2ad-3bd4-48a4-b0af-5fca7c67440b">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF82LTItMS0xLTE_1eebdf03-04b5-4102-8b87-0bc3c6d6c1cc">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3accb05b873c4bcf83b78bc91b8bb7d7_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF82LTQtMS0xLTE_99980288-2c50-47d9-bd4c-c148a8a82fa2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTAtMS0xLTIxNjAw_a096810f-302a-49a3-a80e-cc3fa0b97093">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTItMS0xLTIxNzAx_b44bb3c5-ca56-4f0a-9d92-2a2181ceccbc">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia1271eda59e6456485c83160f2ecfccf_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTQtMS0xLTIxNzEz_7eb746e7-10e9-463f-9741-79868209cfe9">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTAtMS0xLTE_6ad202ad-f876-42f8-930c-be579d77c497">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTItMS0xLTE_03004c35-d1c3-4411-b640-26f48f71a251">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9e895be80a6e40ad90dc22d39f11292f_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF83LTQtMS0xLTE_8e1f5b9f-983b-4eac-af03-52b5bbf1eadb">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie995d89d5c494c239211a78a6682af37_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF85LTAtMS0xLTIxNjky_6bb6ad9d-a892-41bc-9824-2e178791b7ee">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie995d89d5c494c239211a78a6682af37_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF85LTItMS0xLTIxNzA0_99a420c5-0d9a-4f29-b6d2-4efe593b6809">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie995d89d5c494c239211a78a6682af37_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF85LTQtMS0xLTIxNzE2_0a27ec01-a25f-44bf-a24c-8ed1a62449a2">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i37f68d019fc444398a863e31316ec594_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF84LTAtMS0xLTE_24814ba7-9ecd-4fb7-be5a-b78032e12795">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i37f68d019fc444398a863e31316ec594_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF84LTItMS0xLTE_0e5bab82-00a3-40e4-aadc-82d9eb7d8bf5">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i37f68d019fc444398a863e31316ec594_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF84LTQtMS0xLTE_ff8ec5bc-3a5d-4f4c-b476-d7956b243bec">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i014ec31d847549518d3d26c2b459250e_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMS0wLTEtMS0yMTY5NQ_1d79bc23-7d83-452a-b8d4-c1255630ff9a">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i014ec31d847549518d3d26c2b459250e_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMS0yLTEtMS0yMTcwNw_dead5753-7fbf-47a3-84cd-b8609c512a64">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i014ec31d847549518d3d26c2b459250e_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMS00LTEtMS0yMTcxOQ_93d25bf2-9d95-4975-966b-3102badb30a3">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMi0wLTEtMS0yMTY5OA_097e786e-2672-43cb-a79f-6d84bb8cbfac">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMi0yLTEtMS0yMTcxMA_2a12f219-ae93-4d67-bd4a-4dd3fc32e547">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia089c0c9ff06456dba0f12895d8e4e57_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGFibGU6YWIzNmE3ZDljZDcyNDJhZmI4ZmYxYWU0ODI4NjM3ZDAvdGFibGVyYW5nZTphYjM2YTdkOWNkNzI0MmFmYjhmZjFhZTQ4Mjg2MzdkMF8xMi00LTEtMS0yMTcyMg_892ecab1-6a4b-46c5-a3ae-9b566f999e0e">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026"
      id="id3VybDovL2RvY3MudjEvZG9jOjI2ODY0YTM3Njc3YTQzZjBhYTUxYmJmNjc3ZjhiOGFkL3NlYzoyNjg2NGEzNzY3N2E0M2YwYWE1MWJiZjY3N2Y4YjhhZF8xL2ZyYWc6ZmFhNGM5ZWZlMGI3NDk5Zjg4OWMzYjM0ZDI2ZmMyNmUvdGV4dHJlZ2lvbjpmYWE0YzllZmUwYjc0OTlmODg5YzNiMzRkMjZmYzI2ZV8xMTg5_f9b36ded-c8c7-4169-b4b6-cdec85ddaf6d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139959996674808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 26,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'ID,O&_CFOXN6;\L9SH9&1#'D@'!_/9.ZK_.N1R;^?Q-$]3$--LT*IYKH^%
M,AJ8WMY)]9_X."V5C'3Q;J.\W@T$Z*;/;OHW-U]8[_8=N[K[..C=?L%.1L'V
MSDZV-]]N4FM#?YWP)_:!U]:-0%GFGW_FA5TL&<C>P=7<T]V65!WW/HO&M7EP
M #6/SMHI.^%VW?_Z3&>H1/R5O2H$FT:2/4;9C+_&^*!LQSW:-8$#&G9P>]ZG
M2I],BA&SG5</K]F0QS,MYOJ9QDG_LQY@9P?WZKV,$K.4A\_Y@Z@5,P'0*P4+
M EIV<(V^U(A=/\63J!CSK0N8 -U^&5YCB4#'#NY-NZT7V<_L5BA>LF3&S66I
M@Y'!HT[W>$T(2G1PD^W3A#AIWTJXX$07%QG=?@1 MQ\>!23HX@[;O0$)$-&
M+KC0Q5T8,KO3W2@[=@;MKOUH<3P+NF!!MS$+$J2]*P'^<P_U'P$P#8A& 0.Z
M31F0 %$-" 9T*0,&CK]1]@ C@P'=XQG0!0.ZC1F0(.U;"0\,Z!UJ0 )@&A"-
M @;TFC(@ 2(:T ,#>K@!G;:]6787NU#VP(#>\0SHK?TNVY@!"=+>E0 #>H<:
MD #H!L2C@ &]I@Q(@*@&! -ZN &M[]>]B_W&ZX$!O>,9T ,#>HT9D"#M6PD?
M#.@?:D "8!H0C0(&])LR( $B&M ' _JX 8-V&&Y4'9.]#P+TCR= 'P3H-R9
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MU=,)CQ(NS0?T^R.A)V2Y8>YD7=V(?/D?4$L#!!0    ( - X6E.?H!OPL0(
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #0.%I3!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( - X
M6E/4#T%Z[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( - X6E.97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ T#A:4PGT] V9
M!@  E"P  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( - X6E.?H!OPL0(  .(,   -              "
M =P.  !X;"]S='EL97,N>&UL4$L! A0#%     @ T#A:4Y>*NQS     $P(
M  L              ( !N!$  %]R96QS+RYR96QS4$L! A0#%     @ T#A:
M4QE%%?4W 0  )P(   \              ( !H1(  'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( - X6E,D'INBK0   /@!   :              "  044
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( - X6E-E
MD'F2&0$  ,\#   3              "  >H4  !;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@     )  D /@(  #06      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>13</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>12</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20211026.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lly-20211026.htm">lly-20211026.htm</File>
    <File>lly-20211026.xsd</File>
    <File>lly-20211026_def.xml</File>
    <File>lly-20211026_lab.xml</File>
    <File>lly-20211026_pre.xml</File>
    <File>q321lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20211026.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 13,
   "dts": {
    "definitionLink": {
     "local": [
      "lly-20211026_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20211026.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20211026_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20211026_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20211026.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 39,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 11,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20211026",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211026.htm",
      "contextRef": "ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20211026.htm",
      "contextRef": "ia6744fa8512a4f2ba3c58965f59b20d3_D20211026-20211026",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 12,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "terseLabel": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20211026",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-21-000213-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-21-000213-xbrl.zip
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MTVO\(FGIGE;U^^?3T6AN1-^'!U/B*.SW$NQ7*>V6OI:"K=Y1=S!QP]R(B]U
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M\810)#WZ58(-LY)[S]C*^L[.E4-E[X'RNZ%;X/_Q^+\\R^1[W*N;\>:=PWR
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M20(O#5\E%LHJ<VO!'XJ%RVML'K 1Y/>9+EC5 SN!/^VLUUW_/U!+ P04
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M:939;_M@W%N4#OR_Y\0><=:_V687/P%02P,$%     @ T#A:4]I[6<I@"@
M1T\  !0   !L;'DM,C R,3$P,C9?9&5F+GAM;-U<VV[;2!)]SU=H/:_;=M\O
MP3@#KY-9>#<S"1(/9K O0E]M(A1ID%1L__T6*2F^B!Y[S<XLK""0)8JL.GU.
ML;NJV:T??[I:E+.OL6F+NCK<(_MX;Q8K7X>B.CO<^^WT9Z3W?GKSZM6/?T/H
MCW]\>C][6_OE(E;=[+B)MHMA=EETY[/?0VR_S%)3+V:_U\V7XJM%Z,UPT7%]
M<=T49^?=C&)*[G_;O-:.>Z851C$0@G@0&&GI+?+,26)P8-B'OY^]U@Q;14Q
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MN^B/+/]S^4D"\*P\Z$5V_S5?WG[<1AAB=/J_^9-$44T2#H%)$0(TC2%(F)9
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M/M;<4D2!MNJQ2,BJV YB/5S6>'1=.#643!T_!U-ZA!WBW=?HAY*^/IZK@\<
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MY*C+B4L?Y\&<USEJVO25Y@NG]URN7JY3\^5_S-<%,B+A2%' DO+9;2Z!(-0
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M.NKYKRE=G8?66+>J:=KCW4C9)Y,_5YMM+O5V(3&V,767:,E8L16Y++8BAQ1
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MN1__'5ZY3\^^.WSC?BBY,<^^^W]02P,$%     @ T#A:4TZNH!P "@  %E0
M !0   !L;'DM,C R,3$P,C9?<')E+GAM;-6<6U/;2!;'W_,IO,SK'NC[)37)
M%$LR6^R222K)U$SMBZNOH(HM49((\.WWR."$BPD:+$9V*F5 ;NF<\^^?6^=T
MM_SS+Q?SV>1KJINB*E_MT%VR,TEEJ&)1'K_:^?WSKV!V?GG]XL7/_P#X\U\?
MCR9OJG V3V4[.:B3:U.<G!?MR>2/F)HODUQ7\\D?5?VE^.H 7B]..JA.+^OB
M^*2=,,+HW7?KE\:+P(TFD"*E(*(D8%1P$+A7U)+(28C_/'YI.'&:V@C>" V"
MF PV,04Y:JM)R)DGLKCHK"B_O.Q>O&O2!(,KF\6?KW9.VO;TY=[>^?GY[H6O
M9[M5?;S'".%[R]8[U\TO[K4_YXO6U%J[MWCW6].F6-40+TOW_GQW]"F<I+F#
MHFQ:5X;.0%.\;!8'CZK@VH7FC_HU>;!%]Q<LFT%W""@#3G<OFKCS^L5D<B5'
M7<W2QY0GW<_?/Q[>,CDK9K/+W5#-][IW]PXJ9.&#.^Y\79S;7IZF5SM-,3^=
M?3MV4J?\:@?/@ZY/*6&J,_C3]W/WOML^K5.#N"QB/<(#UY?HC#W!CW31IC*F
MJ^"6)F95N-5HUDE;U<LS9\ZGV>+H-*9BNKCROF_:VH5V*I(,/,@(RE(.(KN,
MA'D*,?LH; R!4G\[[,[G!IU>]$23PNYQ]74/+XP]PDCW2R<* 4*O^^&G>T:O
MY'F:]\N/WV&9JWJ^4/6S\[,T]2(GRJ@$*9P 89T&(QP!Q1@31KH8HQX@D(?L
MWX[I9J?OUV%2U3'5.+HL'7!UN ? ;;*O6^R=NAHO!.&DF,7EV=TP,T1_MM7
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MYZ_?R=__^IUXR5\'@3O]_J\N?R3<_=L+;EINV^[T65<W3-NFO;[A.+3K4GW
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MU#\)3?^07FLA;_+T(7%:+AM!%CY=S@E6['L8]OUU"*PG" [MWML(6X8C)W[
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M\+Z/(9@8#FBBO4FG$Z5^'#;#XR/UXB\*1.M E%W8;>5)^"UR-WX0AW\*=.M
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M6!G844BX?OKN(*U-7+(E.;\46@+W\CGBT2<BS"B!%@'' F6Z-*8PTOD$$AP
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M+MYK[U#1K-K2S"7)4JO5:V\ZE*PG?]0#?I<D2^V6WNUL%0@\ JTT*A+85H'
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MA-Z=;(7+E%@72?C-DVB.DF@7)]&J>E&'L\\:,\])J\'78^G/F4>5:U CGY.
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MAM"'W;+[QLEN\"LEUS E9[6Z'4MK*R5W-G+J+)2<V>MNK$AT;"5773THR=<
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M0N9R)V[)F8:$$D2.G =VY[ED1('(X>-D .""W0+<L-Z?$P/!P[CE3<[V$DP
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M03=3/[I^5J3)[)2<=JRW/K>@R^+?H]D!YP1$V?4@9/33-1W"\Z^H]T2GT0*
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MY9']6H?;S:__ U!+ 0(4 Q0    ( - X6E,6N?JNUB   ,(A 0 0
M      "  0    !L;'DM,C R,3$P,C8N:'1M4$L! A0#%     @ T#A:4^+H
MIV;/ P  RQ(  !               ( !!"$  &QL>2TR,#(Q,3 R-BYX<V10
M2P$"% ,4    " #0.%I3VGM9RF *  !'3P  %               @ $!)0
M;&QY+3(P,C$Q,#(V7V1E9BYX;6Q02P$"% ,4    " #0.%I3HP$N(UD1  #&
MJ@  %               @ &3+P  ;&QY+3(P,C$Q,#(V7VQA8BYX;6Q02P$"
M% ,4    " #0.%I33JZ@'  *   65   %               @ $>00  ;&QY
M+3(P,C$Q,#(V7W!R92YX;6Q02P$"% ,4    " #0.%I3)+/JZTMN  "?_P8
M'@              @ %02P  <3,R,6QI;&QY<V%L97-A;F1E87)N:6YG<W N
9:'1M4$L%!@     &  8 C@$  ->Y      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
